SCHEMBL24252491

SCHEMBL24252491

Clc1ccc(Oc2cncs2)c(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.45
SLC6A4 P31645 3/20 0.45
SLC6A3 Q01959 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
ICAM1 P05362 1/20 0.43
SELE P16581 1/20 0.43
VCAM1 P19320 1/20 0.43
ALDH1A1 P00352 4/20 0.38
EPAS1 Q99814 2/20 0.37
SMN1; SMN2 Q16637 5/20 0.37
NPC1 O15118 4/20 0.37
MAPT P10636 4/20 0.37
RAB9A P51151 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PPARA Q07869 1/20 0.35
MAPK1 P28482 1/20 0.35
LMNA P02545 3/20 0.34
HPGD P15428 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3999904 0.84 MAPK1 (0.55) SLC6A2SLC6A4SLC6A3L3MBTL1ALDH1A1
SCHEMBL24252966 0.73 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3L3MBTL1ICAM1
SCHEMBL5570887 0.72 CYP3A4 (0.37) SLC6A2SLC6A4SLC6A3ALDH1A1SMN1; SMN2
SCHEMBL4003143 0.71 HDAC8 (0.35) ALDH1A1
SCHEMBL3995895 0.69 HDAC8 (0.31) MEN1KMT2ATSHR
SCHEMBL24252664 0.69 L3MBTL1 (0.45) SLC6A2SLC6A4SLC6A3L3MBTL1ICAM1
SCHEMBL8054019 0.69 TTR (0.66) SLC6A2SLC6A4SLC6A3L3MBTL1ALDH1A1
SCHEMBL21670812 0.67 L3MBTL1 (0.48) SLC6A2SLC6A4SLC6A3L3MBTL1ICAM1
SCHEMBL22010909 0.66 LTA4H (0.41) SLC6A2SLC6A4SLC6A3ICAM1SELE
SCHEMBL19271959 0.66 PPARA (0.43) SLC6A2SLC6A4SLC6A3L3MBTL1ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SLC6A2 2384/4885SLC6A4 2319/4885SLC6A3 2604/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SLC6A2 2384/4885SLC6A4 2319/4885SLC6A3 2604/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SLC6A2 2384/4885SLC6A4 2319/4885SLC6A3 2604/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH SLC6A2 4261/4885SLC6A4 4273/4885SLC6A3 4149/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 SLC6A2 1457/4885SLC6A4 1550/4885SLC6A3 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.